Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Inmune Bio (INMB) over the last 9 years, with Q3 2025 value amounting to $26.6 million.

  • Inmune Bio's Shares Outstanding (Weighted Average) rose 3170.36% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.6 million, marking a year-over-year increase of 3170.36%. This contributed to the annual value of $19.9 million for FY2024, which is 1092.01% up from last year.
  • Inmune Bio's Shares Outstanding (Weighted Average) amounted to $26.6 million in Q3 2025, which was up 3170.36% from $23.3 million recorded in Q2 2025.
  • In the past 5 years, Inmune Bio's Shares Outstanding (Weighted Average) registered a high of $26.6 million during Q3 2025, and its lowest value of $14.3 million during Q1 2021.
  • For the 5-year period, Inmune Bio's Shares Outstanding (Weighted Average) averaged around $18.7 million, with its median value being $17.9 million (2022).
  • In the last 5 years, Inmune Bio's Shares Outstanding (Weighted Average) skyrocketed by 3864.79% in 2021 and then changed by 0.0% in 2023.
  • Inmune Bio's Shares Outstanding (Weighted Average) (Quarter) stood at $16.1 million in 2021, then grew by 11.14% to $17.9 million in 2022, then rose by 0.3% to $18.0 million in 2023, then increased by 10.92% to $19.9 million in 2024, then surged by 33.3% to $26.6 million in 2025.
  • Its last three reported values are $26.6 million in Q3 2025, $23.3 million for Q2 2025, and $22.5 million during Q1 2025.